Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

E 047/1: a new class III antiarrhythmic agent.

H Domanovits1, M Schillinger, P Lercher

  • 1Emergency Department, Vienna General Hospital-University of Vienna Medical School, Austria. Hans.Domanovits@akh-wien.ac.at

Journal of Cardiovascular Pharmacology
|May 17, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Arterial stiffness in acute COVID-19 and potential associations with clinical outcome.

Journal of internal medicine·2021
Same author

[Aspects of intensive care medicine in emergency medicine].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2020
Same author

Hemodynamic effects of Vernakalant in cardio-surgical ICU-patients treated for recent-onset postoperative atrial fibrillation.

Scientific reports·2020
Same author

Imbalance between plasma double-stranded DNA and deoxyribonuclease activity predicts mortality after out-of-hospital cardiac arrest.

Resuscitation·2020
Same author

State of the art: leadless ventricular pacing : A national expert consensus of the Austrian Society of Cardiology.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2019
Same author

Time of out-of-hospital cardiac arrest is not associated with outcome in a metropolitan area: A multicenter cohort study.

Resuscitation·2019
Same journal

Integration of Mendelian Randomization and FAERS Database Analysis Reveals the Association Between Ergotamine and Aortic and Mitral Valve Diseases.

Journal of cardiovascular pharmacology·2026
Same journal

A Comprehensive Review of PCSK9 Inhibitor Therapy.

Journal of cardiovascular pharmacology·2026
Same journal

SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study.

Journal of cardiovascular pharmacology·2026
Same journal

Aspirin in primary prevention: a case for selective use.

Journal of cardiovascular pharmacology·2026
Same journal

GLP-1 Gene Therapy Trial for Obesity and Type 2 Diabetes: Towards a New Paradigm for Chronic Disease Treatment.

Journal of cardiovascular pharmacology·2026
Same journal

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis.

Journal of cardiovascular pharmacology·2026
See all related articles

E 047/1, an amiodarone derivative, effectively treated acute arrhythmias in 50% of patients. This drug demonstrated rapid elimination, mild side effects, and good local tolerability, making it a safe option for arrhythmia management.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acute supraventricular and ventricular arrhythmias pose significant clinical challenges.
  • Amiodarone derivatives are explored for improved safety and efficacy profiles.

Purpose of the Study:

  • To evaluate the efficacy, pharmacokinetics, safety, and tolerability of E 047/1, an amiodarone derivative.
  • To assess E 047/1 in patients experiencing acute supraventricular or ventricular arrhythmias.

Main Methods:

  • An open, nonrandomized prospective multicenter trial involving 20 patients.
  • Treatment with three different intravenous dosage regimens of E 047/1.
  • Assessment of arrhythmia termination, drug plasma levels, vital signs, ECG parameters, and adverse events.

Main Results:

Related Experiment Videos

  • Therapeutic success was achieved in 10 (50%) patients.
  • E 047/1 exhibited rapid plasma elimination within 1 hour.
  • No significant changes in blood pressure or ECG parameters were observed; no proarrhythmic effects noted.
  • Adverse events included mild nausea, vomiting, vertigo, and transient hypotension in a small number of patients, primarily with high-dose bolus regimens.
  • Excellent local tolerability at the infusion site was reported.

Conclusions:

  • E 047/1 is an efficient and safe option for treating acute arrhythmias.
  • The drug is characterized by rapid elimination, lack of cardiodepressive effects, and a favorable safety profile.
  • A combined bolus- and weight-adapted infusion regimen is recommended for further investigation.